HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTCs Under Threat In Europe: Calls To Reverse-Switch Codeine And Others In Poland And Ireland

Executive Summary

Poland's ministry of health is calling for codeine, dextromethorphan and pseudoephedrine to be reverse-switched from OTC to prescription status in response to abuse of the drugs by adolescents. At the same time, an academic paper argues Ireland should restrict codeine to prescription-only sale to combat an addiction epidemic "verging on eruption."

You may also be interested in...



OTC Codeine Is 'Safe And Effective' – UK Industry Responds To BBC Exposé

Will the UK follow other countries and reverse-switch codeine to prescription-only status? British industry association, the PAGB, responds to a BBC documentary questioning the safety and efficacy of OTC codeine.

New Zealand Reverse-Switches Codeine Judging Risks Outweigh Benefits

New Zealand is the latest country to reverse-switch all codeine-containing OTC drugs to prescription-only status following a protracted consultation process, during which industry's protestations fell on deaf ears.

France's ANSM Moves Paracetamol, Ibuprofen And Aspirin Behind The Counter

France restricts sales of medicines containing paracetamol, ibuprofen and aspirin to behind the pharmacy counter due to safety concerns.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel